147 related articles for article (PubMed ID: 2885419)
1. Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.
Evans BE; Rittle KE; Bock MG; DiPardo RM; Freidinger RM; Whitter WL; Gould NP; Lundell GF; Homnick CF; Veber DF
J Med Chem; 1987 Jul; 30(7):1229-39. PubMed ID: 2885419
[TBL] [Abstract][Full Text] [Related]
2. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
Evans BE; Rittle KE; Bock MG; DiPardo RM; Freidinger RM; Whitter WL; Lundell GF; Veber DF; Anderson PS; Chang RS
J Med Chem; 1988 Dec; 31(12):2235-46. PubMed ID: 2848124
[TBL] [Abstract][Full Text] [Related]
3. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.
Evans BE; Bock MG; Rittle KE; DiPardo RM; Whitter WL; Veber DF; Anderson PS; Freidinger RM
Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4918-22. PubMed ID: 3014519
[TBL] [Abstract][Full Text] [Related]
4. Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists.
Sinha J; Kurup A; Paleti A; Gupta SP
Bioorg Med Chem; 1999 Jun; 7(6):1127-30. PubMed ID: 10428383
[TBL] [Abstract][Full Text] [Related]
5. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Veber DF; Freidinger RM; Chang RS; Lotti VJ
J Med Chem; 1988 Jan; 31(1):176-81. PubMed ID: 3336017
[TBL] [Abstract][Full Text] [Related]
7. Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactams.
Parsons WH; Patchett AA; Holloway MK; Smith GM; Davidson JL; Lotti VJ; Chang RS
J Med Chem; 1989 Aug; 32(8):1681-5. PubMed ID: 2754692
[TBL] [Abstract][Full Text] [Related]
8. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
[TBL] [Abstract][Full Text] [Related]
9. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
[TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility.
Bock MG; DiPardo RM; Rittle KE; Evans BE; Freidinger RM; Veber DF; Chang RS; Chen TB; Keegan ME; Lotti VJ
J Med Chem; 1986 Oct; 29(10):1941-5. PubMed ID: 3761313
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
Ursini A; Capelli AM; Carr RA; Cassarà P; Corsi M; Curcuruto O; Curotto G; Dal Cin M; Davalli S; Donati D; Feriani A; Finch H; Finizia G; Gaviraghi G; Marien M; Pentassuglia G; Polinelli S; Ratti E; Reggiani AM; Tarzia G; Tedesco G; Tranquillini ME; Trist DG; Van Amsterdam FT
J Med Chem; 2000 Oct; 43(20):3596-613. PubMed ID: 11020274
[TBL] [Abstract][Full Text] [Related]
12. Molecular design of potent specific antagonists for the gastrin and cholecystokinin receptors.
Evans BE
Z Gastroenterol Verh; 1991 Mar; 26():269-71. PubMed ID: 1714170
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
[TBL] [Abstract][Full Text] [Related]
14. Cholecystokinin antagonists: pharmacological and therapeutic potential.
Herranz R
Med Res Rev; 2003 Sep; 23(5):559-605. PubMed ID: 12789687
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DF; Freidinger RM; Chang RS; Chen TB; Lotti VJ
J Med Chem; 1990 Jan; 33(1):450-5. PubMed ID: 2153212
[TBL] [Abstract][Full Text] [Related]
16. Asperlicin, a nonpeptidal cholecystokinin receptor antagonist, attenuates sodium taurocholate-induced acute pancreatitis in rats.
Wisner JR; Renner IG
Pancreas; 1988; 3(2):174-9. PubMed ID: 2453874
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
Chang RS; Lotti VJ
Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
[TBL] [Abstract][Full Text] [Related]
18. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260.
Lotti VJ; Chang RS
Eur J Pharmacol; 1989 Mar; 162(2):273-80. PubMed ID: 2721567
[TBL] [Abstract][Full Text] [Related]
19. Biological activity of analogues of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists.
Satoh M; Okamoto Y; Koshio H; Ohta M; Nishida A; Akuzawa S; Miyata K; Mase T; Semple G
Chem Pharm Bull (Tokyo); 1996 Jul; 44(7):1412-4. PubMed ID: 8706146
[TBL] [Abstract][Full Text] [Related]
20. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus.
Chang RS; Lotti VJ; Monaghan RL; Birnbaum J; Stapley EO; Goetz MA; Albers-Schönberg G; Patchett AA; Liesch JM; Hensens OD
Science; 1985 Oct; 230(4722):177-9. PubMed ID: 2994227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
